Annovis Bio, Inc. (NYSE: ANVS)

This investigation is for anyone who acquired securities in Annovis Bio, Inc. (NYSE: ANVS) prior to April 29, 2024.

The Law Offices of Howard G. Smith believes that the Company and certain of its executives violated federal law. Specifically, the Law Offices of Howard G. Smith believes that the Company misled investors regarding its financial condition. More specifically, the Law Offices of Howard G. Smith believes that the Company misled investors by telling investors that its Alzheimer’s drug, buntanetap, was effective in clinical trials when the Company knew that the drug was only effective with a small subset of the trial group.

On April 29, 2024, Annovis announced that its Alzheimer’s drug, buntanetap, had shown significant results in a subgroup of patients. However, the subgroup was a fraction of the total planned patients, indicating that the drug failed to show statistical significance in meeting its endpoints. On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Annovis Bio, Inc. (NYSE: ANVS) prior to April 29, 2024 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.